All Trials

A Phase 1b/2 Open-Label Clinical Study to Evaluate the Safety and Efficacy of MK-6070 and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed/refractory extensive-stage SCLC after ≥1 prior systemic therapy (including platinum) receive gocatamig (HPN328; trispecific DLL3×CD3 T‑cell engager with albumin-binding for half-life) as monotherapy or combined with ifinatamab deruxtecan (B7‑H3–targeted DXd ADC) or with durvalumab (PD‑L1 inhibitor). Key exclusions include uncontrolled effusions, significant/suspected ILD/pneumonitis, major cardiopulmonary disease/events, uncontrolled brain mets, active infections/viral hepatitis, and recent chemo/radiation; archival or fresh tumor tissue required.

ClinicalTrials.gov ID: NCT06780137

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With YL201 With or Without Anti-PD-L1 in Subjects With Extensive Stage Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with extensive-stage SCLC: Parts 1–2 enroll those progressed after ≥1 platinum regimen; Part 3 enrolls first-line patients after exactly one cycle of platinum/etoposide plus PD-(L)1. Investigational therapy combines tarlatamab (DLL3×CD3 bispecific T-cell engager) with YL201 (B7-H3–targeting topoisomerase I ADC) with or without anti–PD-L1 (atezolizumab or durvalumab).

ClinicalTrials.gov ID: NCT06898957

A Phase 1 Dose Escalation Study of the Tolerability, Safety, Efficacy and Pharmacokinetics of ZG006 in Patients With Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with DLL3-positive small cell lung cancer that has progressed after or is intolerant to standard therapies receive ZG006 (alveltamig), a trispecific T‑cell engager targeting two DLL3 epitopes and CD3, in a dose-escalation study. Suitable for ECOG 0–1 patients; key exclusions include active infections, recent immunosuppression, and prior severe immune-mediated events.

ClinicalTrials.gov ID: NCT06592638

Phase I Trial of [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic or inoperable somatostatin receptor–positive tumors (GI NETs, pheochromocytoma/paraganglioma, small cell lung, renal cell, and select head/neck cancers) confirmed by SSTR PET receive [212Pb]VMT-Alpha-NET, an SSTR2-targeted alpha-emitting radioligand (212Pb→212Bi) given IV every 8 weeks for up to 4 cycles, with an optional [203Pb] imaging/dosimetry lead-in. Excludes prior systemic radioligand therapy; allows treated/stable or asymptomatic CNS mets and requires adequate organ function.

ClinicalTrials.gov ID: NCT06479811

A Phase I Dose Finding and Phase II Randomized Trial of Iadademstat Combined With Immune Checkpoint Inhibition Maintenance After Initial Chemoimmunotherapy in Patients With Extensive-Stage Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with extensive-stage SCLC who achieved at least stable disease after 4–6 cycles of first-line platinum/etoposide plus atezolizumab or durvalumab receive maintenance PD-L1 inhibitor with or without iadademstat. Iadademstat is an oral covalent LSD1 (KDM1A) inhibitor that modulates SCLC neuroendocrine programs (e.g., activates NOTCH, suppresses ASCL1); treated/stable brain metastases and controlled HIV/HBV/HCV allowed.

ClinicalTrials.gov ID: NCT06287775

An Open-Label, Multicenter, Phase Ib Dose Randomization Study of Bulumtatug Furvedotin (BFv; 9MW2821) in Subjects With Recurrent or Metastatic Triple-Negative Breast Cancer Previously Treated With Antibody-Drug Conjugates

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with recurrent/metastatic triple‑negative breast cancer previously treated with a taxane and a topoisomerase‑inhibitor ADC (ECOG 0–1) receive bulumtatug fuvedotin (9MW2821), a Nectin‑4–targeted MMAE antibody‑drug conjugate, at two dose levels. Excludes prior MMAE‑based or Nectin‑4 ADC exposure and requires measurable disease and available tissue; explores efficacy with biomarker correlations (including Nectin‑4 expression).

ClinicalTrials.gov ID: NCT06908928

A Phase 1b/2, Open-Label, Multicohort Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with previously treated, locally advanced/metastatic breast cancer across HER2+ to HER2-low/ultralow (cohorts by HER2 and HR status, generally after standard HER2 therapies and/or CDK4/6i, PARPi, checkpoint inhibitors, and prior T-DXd as applicable). Single-arm disitamab vedotin (HER2-targeted MMAE antibody–drug conjugate) IV q2w until progression; excludes active CNS disease and prior MMAE ADCs.

ClinicalTrials.gov ID: NCT06966453

A Phase Ib/II Multicenter, Open-Label, Randomized Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-4198 Alone and in Combination With Giredestrant in Comparison With Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive, HER2-Negative Breast Cancer Who Have Previously Progressed During or After a CDK4/6 Inhibitor

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ER-positive, HER2-negative locally advanced/metastatic breast cancer who have progressed on prior CDK4/6 inhibitor plus endocrine therapy (ECOG 0–1) are enrolled to receive GDC-4198—an oral next-generation cyclin-dependent kinase inhibitor with potent CDK4 and additional CDK2 activity—alone or with the oral SERD giredestrant, and in Phase II are randomized to GDC-4198 + giredestrant (two dose levels) versus abemaciclib + giredestrant. Excludes visceral crisis requiring chemotherapy and prior chemotherapy for metastatic disease.

ClinicalTrials.gov ID: NCT07100106

A Phase I/II, Randomized, Multi-site Trial to Investigate the Efficacy and Safety of BNT314 in Combination With BNT327 and Chemotherapy in Participants With Metastatic Colorectal Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable, MSS/pMMR metastatic colorectal adenocarcinoma (ECOG 0–1) are treated with BNT314 (bispecific EpCAM×4‑1BB agonist delivering EpCAM-restricted costimulation) plus BNT327 (bispecific PD‑L1×VEGF‑A inhibitor) with standard chemotherapy across lines of therapy, with Phase 2 randomization versus bevacizumab + chemotherapy or BNT327 + chemotherapy. Excludes MSI‑H/dMMR and prior EpCAM/4‑1BB, checkpoint inhibitor, or PD‑(L)1/VEGF bispecific exposure, and patients with uncontrolled CNS disease or significant cardiovascular/autoimmune risks.

ClinicalTrials.gov ID: NCT07079631

Safely Optimizing Body Weight With TCMCB07 in Patients With Newly Diagnosed Metastatic Colorectal Cancer Undergoing Chemotherapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: Adults with newly diagnosed metastatic colorectal adenocarcinoma starting first-line q2‑week chemotherapy (FOLFOX/FOLFIRI/FOLFIRINOX ± bevacizumab/other biologics), ECOG 0–2 and BMI ≤29, are randomized at cycle 2 to daily subcutaneous TCMCB07 (mifomelatide) vs placebo for 12 weeks to preserve body weight and composition. TCMCB07 is a brain-penetrant cyclic peptide antagonist of MC4R/MC3R intended to counter cancer/chemo‑related anorexia and hypermetabolism; safety and weight change at 12 weeks are primary outcomes.

ClinicalTrials.gov ID: NCT06937177